OF SHARED RESOURCE Since the inception of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Cell Imaging Core Facility in September of 1999, its mission has been to provide state-of-the-art cell imaging technologies to SKCCC members. Services include light and fluorescence microscopy, stereo and confocal microscopy, infrared imaging, time lapse, and laser microdissection. Images can be acquired using a variety of video and CCD cameras, and then analyzed and manipulated with cutting edge image analysis software programs. All scientists have the opportunity for consultation prior to and during their experiments. Users receive technical support by the Core personnel and detailed instruction in the use of all Core equipment. The Core manager routinely monitors the performance of the facility's equipment and regularly receives updated technical training from manufacturers in order to meet the constantly evolving needs of the SKCCC membership. In 2010, 53 different groups led by Principal Investigators from all Programs of the Center have benefited from these Core services. Lay: The Cell Imaging Core provides Cancer Center investigators with supported access to equipment that allows the visualization and imaging of cells and tissues in a wide variety of samples. SKCCC Managed Shared Resource Current Grant Year Reporting Period: January 1, 2010 to December 31, 2010.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-52
Application #
8858527
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
52
Fiscal Year
2015
Total Cost
$117,374
Indirect Cost
$44,921
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225

Showing the most recent 10 out of 2393 publications